
Compelling
7.3#9 in sales prospecting softwareFrom €39 a monthFree planWebAPI
Visit
| Fact | Compelling | Datanyze |
|---|---|---|
| Company size | LinkedIn lists Compelling as a privately held software-development company with 2–10 employees. | LinkedIn lists Datanyze as an 11–50 employee privately held company. |
| Integrations | Compelling says it connects CRM, outreach and data tools, with examples including HubSpot, Salesforce and Pipedrive. | The terms say Datanyze may provide tools that let its technology interoperate with third-party applications, including CRM, marketing automation, or sales enablement software. |
| Licence | Compelling grants customers a non-exclusive, non-transferable licence to use the service; the terms prohibit copying, mirroring and unauthorized resale. | The terms grant a limited right to use Datanyze technology and prohibit reverse engineering, derivative works, redistribution and automated extraction. |
| Notable news | A LinkedIn company update said the MCP launched on all plans and reported more than 500 organizations using the platform in 2026. | Crunchbase records a Business Wire announcement dated September 26, 2018 about ZoomInfo's acquisition of Datanyze. |
| Product | Compelling is an AI-native sales intelligence platform that automates company and contact research, ranking, and enrichment, then pushes tailored insights to a CRM. | Datanyze is a Google Chrome extension for finding B2B contact details such as email addresses, direct dial phone numbers, and company details from sites such as LinkedIn. |
| Rating on Capterra | 0.0 out of 5 from 0 reviews | 3.7 out of 5 from 52 reviews |
Compelling suits sales teams that need to research and score target accounts, monitor user-defined buying signals, and send insights to a CRM. It may also suit users who want to access research through Claude, ChatGPT, or Gemini.
Datanyze may suit B2B sales and prospecting users who need contact and company details, segmented lists, or technology signals. It is for people using Google Chrome and should be evaluated with the trial’s access limits in mind.